← 治験一覧に戻る
転移性HER2陽性乳がん患者を対象とした、パトリツマブ デルクステカンと他の抗がん剤の併用試験（MK-1022-009）
基本情報
- NCT ID
- NCT06686394
- ステータス
- 募集中
- 試験のフェーズ
- 第1/第2相
- 試験タイプ
- 介入
- 目標被験者数
- 81
- 治験依頼者名
- Merck Sharp & Dohme LLC
概要
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
対象疾患
乳がん乳癌
介入
Patritumab deruxtecan(BIOLOGICAL)
Trastuzumab(BIOLOGICAL)
Trastuzumab Biosimilar(BIOLOGICAL)
Pertuzumab(BIOLOGICAL)
Tucatinib(BIOLOGICAL)
実施施設 (1)
名古屋市立大学病院
Nagoya, Aichi-ken, Japan(RECRUITING)